GH Research (NASDAQ:GHRS) Stock Price Down 8.9%

GH Research PLC (NASDAQ:GHRSGet Rating)’s stock price fell 8.9% during trading on Tuesday . The stock traded as low as $12.89 and last traded at $12.89. 27 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 31,645 shares. The stock had previously closed at $14.15.

Analysts Set New Price Targets

Several research firms have commented on GHRS. HC Wainwright began coverage on shares of GH Research in a report on Tuesday, August 16th. They issued a “buy” rating and a $45.00 price objective on the stock. Roth Capital began coverage on shares of GH Research in a report on Wednesday, June 15th. They issued a “buy” rating and a $66.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $46.60.

GH Research Price Performance

The stock’s 50-day moving average price is $12.95 and its 200-day moving average price is $13.58. The company has a market cap of $697.70 million, a P/E ratio of -60.04 and a beta of 0.91.

GH Research (NASDAQ:GHRSGet Rating) last announced its earnings results on Tuesday, August 23rd. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. As a group, analysts expect that GH Research PLC will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its position in shares of GH Research by 2.2% in the second quarter. Citadel Advisors LLC now owns 1,303,470 shares of the company’s stock valued at $13,009,000 after acquiring an additional 27,738 shares during the period. Virtus ETF Advisers LLC lifted its position in GH Research by 48.8% during the second quarter. Virtus ETF Advisers LLC now owns 9,952 shares of the company’s stock worth $99,000 after purchasing an additional 3,265 shares during the period. AdvisorShares Investments LLC lifted its position in GH Research by 28.2% during the second quarter. AdvisorShares Investments LLC now owns 24,835 shares of the company’s stock worth $248,000 after purchasing an additional 5,461 shares during the period. Tortoise Investment Management LLC bought a new stake in GH Research during the second quarter worth about $41,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in GH Research by 16.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 159,001 shares of the company’s stock worth $1,587,000 after purchasing an additional 22,392 shares during the period. Institutional investors own 70.08% of the company’s stock.

GH Research Company Profile

(Get Rating)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Recommended Stories

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.